Current review of in vivo GBM rodent models: Emphasis on the CNS-1 tumour model

ASN Neuro

Volumn 3, Issue 3, 2011, Pages 171-181

  Jacobs, Valerie L ^a   Valdes, Pablo A ^a,b   Hickey, William F ^a   de Leo, Joyce A ^a,c,d  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH COLLEGE   (United States)

^c Neuroscience Center at Dartmouth   (United States)

^d DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

9L; C6; CNS 1; GL261; U251; U87

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; PROTEIN S100B; TUMOR MARKER; VIMENTIN;

CANCER CELL CULTURE; CANCER GENETICS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER MORPHOLOGY; CELL STRAIN 9L; CELL STRAIN C6; CELL STRAIN CNS 1; CELL STRAIN GL261; CELL STRAIN U251; CELL STRAIN U87; CLINICAL FEATURE; GENE MUTATION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; RODENT; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ANIMAL; BRAIN TUMOR; CLINICAL TRIAL (TOPIC); DISEASE MODEL; GENETICS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; GLIOBLASTOMA; HUMANS;

EID: 80052979540     PISSN: None     EISSN: 17590914     Source Type: Journal    
DOI: 10.1042/AN20110014     Document Type: Review

References (92)

1. Ali S, Curtin JF, Zirger JM, Xiong W, King GD, Barcia C, Liu C, Puntel M, Goverdhana S, Lowenstein PR, Castro MG (2004) Inflammatory and antiglioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Mol Ther 10:1071-1084.
2. Asai A, Miyagi Y, Sugiyama A, Gamanuma M, Hong SH, Takamoto S, Nomura K, Matsutani M, Takakura K, Kuchino Y (1994) Negative effects of wildtype p53 and s-Myc on cellular growth and tumorigenicity of glioma cells. Implication of the tumor suppressor genes for gene therapy. J Neurooncol 19:259-268.
3. Auer RN, Del Maestro RF, Anderson R (1981) A simple and reproducible experimental in vivo glioma model. Can J Neurol Sci 8:325-331.
4. Barth RF (1998) Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J Neurooncol 36:91-102.
5. Benda P, Lightbody J, Sato G, Levine L, Sweet W (1968) Differentiated rat glial cell strain in tissue culture. Science 161:370-371.
6. Benda P, Someda K, Messer J, Sweet WH (1971) Morphological and immunochemical studies of rat glial tumors and clonal strains propagated in culture. J Neurosurg 34:310-323.
7. Beranek JT (2002) Endothelial hyperplasia: an important indicator of actual angiogenesis. Br J Cancer 86:658.
8. Biglari A, Bataille D, Naumann U, Weller M, Zirger J, Castro MG, Lowenstein PR (2004) Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. Cancer Gene Ther 11:721-732.
9. Bisland SK, Goebel EA, Hassanali NS, Johnson C, Wilson BC (2007) Increased expression of mitochondrial benzodiazepine receptors following low-level light treatment facilitates enhanced protoporphyrin IX production in glioma-derived cells in vitro. Lasers Surg Med 39:678-684.
10. Branle F, Lefranc F, Camby I, Jeuken J, Geurts-Moespot A, Sprenger S, Sweep F, Kiss R, Salmon I (2002) Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. Cancer 95:641-655.
11. Brat DJ, Van Meir EG (2004) Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest 84:397-405.
12. Burger PC, Scheithauer BW, Vogel FS (2002) Surgical Pathology of the Nervous System and its Coverings, pp. 687, Churchill Livingstone, New York.
13. Camphausen K, Purow B, Sproull M, Scott T, Ozawa T, Deen DF, Tofilon PJ (2005) Influence of in vivo growth on human glioma cell line gene expression: convergent profiles under orthotopic conditions. Proc Natl Acad Sci USA 102:8287-8292.
14. Candolfi M, Curtin JF, Nichols WS, Muhammad AG, King GD, Pluhar GE, McNiel EA, Ohlfest JR, Freese AB, Moore PF, Lerner J, Lowenstein PR, Castro MG (2007) Intracranial glioblastoma models in preclinical neurooncology: neuropathological characterization and tumor progression. J Neurooncol 85:133-148.
15. Carpentier AF, Xie J, Mokhtari K, Delattre JY (2000) Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res 6:2469-2473.
16. Chicoine MR, Silbergeld DL (1995) Invading C6 glioma cells maintaining tumorigenicity. J Neurosurg 83:665-671.
17. Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, Mischel PS (2003) Analysis of the phosphatidylinositol 39-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63:2742-2746.
18. Chou YH, Khuon S, Herrmann H, Goldman RD (2003) Nestin promotes the phosphorylation-dependent disassembly of vimentin intermediate filaments during mitosis. Mol Biol Cell 14:1468-478.
19. Clark MJ, Homer N, O'Connor BD, Chen Z, Eskin A, Lee H, Merriman B, Nelson SF (2010) U87MG decoded: the genomic sequence of a cytogenetically aberrant human cancer cell line. PLoS Genet 6:e1000832.
20. de Vries NA, Beijnen JH, van Tellingen O (2009) High-grade glioma mouse models and their applicability for preclinical testing. Cancer Treat Rev 35:714-723.
21. DeAngelis LM (2001) Brain tumors. N Engl J Med 344:114-123.
22. Demeule M, Regina A, Annabi B, Bertrand Y, Bojanowski MW, Beliveau R (2004) Brain endothelial cells as pharmacological targets in brain tumors. Mol Neurobiol 30:157-183.
23. Denlinger RH, Axler DA, Koestner A, Liss L (1975) Tumor-specific transplantation immunity to intracerebral challenge with cells from a methylnitrosourea-induced brain tumor. J Med 6:249-259.
24. Dunn JF, O'Hara JA, Zaim-Wadghiri Y, Lei H, Meyerand ME, Grinberg OY, Hou H, Hoopes PJ, Demidenko E, Swartz HM (2002) Changes in oxygenation of intracranial tumors with carbogen: a BOLD MRI and EPR oximetry study. J Magn Reson Imaging 16:511-521.
25. Ecsedy JA, Holthaus KA, Yohe HC, Seyfried TN (1999) Expression of mouse sialic acid on gangliosides of a human glioma grown as a xenograft in SCID mice. J Neurochem 73:254-259.
26. Fueyo J, Gomez-Manzano C, Yung WK, Clayman GL, Liu TJ, Bruner J, Levin VA, Kyritsis AP (1996) Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene 12:103-110.
27. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21:2683-2710.
28. Ghods AJ, Irvin D, Liu G, Yuan X, Abdulkadir IR, Tunici P, Konda B, Wachsmann-Hogiu S, Black KL, Yu JS (2007) Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells. Stem Cells 25:1645-1653.
29. Grobben B, De Deyn PP, Slegers H (2002) Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion. Cell Tissue Res 310:257-270.
30. Han SJ, Yang I, Tihan T, Prados MD, Parsa AT (2010) Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity. J Neurooncol 96:313-320.
31. Harada K, Yoshida J, Mizuno M, Sugita K, Kurisu K, Uozumi T (1994) Growth inhibition of subcutaneously transplanted human glioma by transfectioninduced tumor necrosis factor-alpha and augmentation of the effect by gamma-interferon. J Neurooncol 22:221-225.
32. Henderson SD, Kimler BF, Morantz RA (1981) Radiation therapy of 9L rat brain tumors. Int J Radiat Oncol Biol Phys 7:497-502.
33. Homma T, Fukushima T, Vaccarella S, Yonekawa Y, Di Patre PL, Franceschi S, Ohgaki H (2006) Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol 65:846-854.
34. Houchens DP, Ovejera AA, Riblet SM, Slagel DE (1983) Human brain tumor xenografts in nude mice as a chemotherapy model. Eur J Cancer Clin Oncol 19:799-805.
35. Husain SR, Behari N, Kreitman RJ, Pastan I, Puri RK (1998) Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy. Cancer Res 58:3649-3653.
36. ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 9:469-479.
37. Jaworski DM, Kelly GM, Piepmeier JM, Hockfield S (1996) BEHAB (brain enriched hyaluronan binding) is expressed in surgical samples of glioma and in intracranial grafts of invasive glioma cell lines. Cancer Res 56:2293-2298.
38. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358:2039-2049.
39. Kielian T, van Rooijen N, Hickey WF (2002) MCP-1 expression in CNS-1 astrocytoma cells: implications for macrophage infiltration into tumors in vivo. J Neurooncol 56:1-12.
40. Kimler BF, Liu C, Evans RG, Morantz RA (1992) Intracerebral chemotherapy in the 9L rat brain tumor model. J Neurooncol 14:191-200.
41. King GD, Muhammad AK, Curtin JF, Barcia C, Puntel M, Liu C, Honig SB, Candolfi M, Mondkar S, Lowenstein PR, Castro MG (2008) Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. Neuro Oncol 10:19-31.
42. Kleihues P, Cavenee WK, International Agency for Research on Cancer (2000) Pathology and Genetics of Tumours of the Nervous System, pp. 314, IARC Press, Lyon.
43. Koul D, Shen R, Bergh S, Sheng X, Shishodia S, Lafortune TA, Lu Y, de Groot JF, Mills GB, Yung WK (2006) Inhibition of Akt survival pathway by a smallmolecule inhibitor in human glioblastoma. Mol Cancer Ther 5:637-644.
44. Krakstad C, Chekenya M (2010) Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol Cancer 9:135.
45. Kruse CA, Mitchell DH, Kleinschmidt-DeMasters BK, Bellgrau D, Eule JM, Parra JR, Kong Q, Lillehei KO (1993) Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma. J Neurooncol 15:97-112.
46. Kruse CA, Molleston MC, Parks EP, Schiltz PM, Kleinschmidt-DeMasters BK, Hickey WF (1994) A rat glioma model, CNS-1, with invasive characteristics similar to those of human gliomas: a comparison to 9L gliosarcoma. J Neurooncol 22:191-200.
47. Lapointe M, Lanthier J, Moumdjian R, Regina A, Desrosiers RR (2005) Expression and activity of l-isoaspartyl methyltransferase decrease in stage progression of human astrocytic tumors. Brain Res Mol Brain Res 135:93-103.
48. Lo HW (2010) EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance. Curr Mol Pharmacol 3:37-52.
49. Louis DN (1994) The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 53:11-21.
50. Louis DN, Holland EC, Cairncross JG (2001) Glioma classification: a molecular reappraisal. Am J Pathol 159:779-786.
51. Maes W, Van Gool SW (2011) Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model. Cancer Immunol Immunother 60:153-160.
52. Moore XL, Lu J, Sun L, Zhu CJ, Tan P, Wong MC (2004) Endothelial progenitor cells' 'homing' specificity to brain tumors. Gene Ther 11:811-818.
53. Nagano N, Sasaki H, Aoyagi M, Hirakawa K (1993) Invasion of experimental rat brain tumor: early morphological changes following microinjection of C6 glioma cells. Acta Neuropathol 86:117-125.
54. Newcomb EW, Zagzag D (2009) The murine GL261 glioma experimental model to assess novel brain tumor treatments. In CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches (Meir EG, ed), pp. 227-241, Springer, Dordrecht.
55. Nutt CL, Zerillo CA, Kelly GM, Hockfield S (2001) Brain enriched hyaluronan binding (BEHAB)/brevican increases aggressiveness of CNS-1 gliomas in Lewis rats. Cancer Res 61:7056-7059.
56. Owens GC, Orr EA, DeMasters BK, Muschel RJ, Berens ME, Kruse CA (1998) Overexpression of a transmembrane isoform of neural cell adhesion molecule alters the invasiveness of rat CNS-1 glioma. Cancer Res 58:2020-2028.
57. Parsa AT, Chakrabarti I, Hurley PT, Chi JH, Hall JS, Kaiser MG, Bruce JN (2000) Limitations of the C6/Wistar rat intracerebral glioma model: implications for evaluating immunotherapy. Neurosurgery 47:993-999.
58. Pfeiffer SE, Herschman HR, Lightbody J, Sato G (1970) Synthesis by a clonal line of rat glial cells of a protein unique to the nervous system. J Cell Physiol 75:329-339.
59. Ponten J (1975) Neoplastic human glia cells in culture. In Human Tumor Cells in Vitro (Fogh J, ed), pp. 175-185, Plenum Press, New York.
60. Puntel M, Muhammad AK, Candolfi M, Salem A, Yagiz K, Farrokhi C, Kroeger KM, Xiong W, Curtin JF, Liu C, Bondale NS, Lerner J, Pechnick RN, Palmer D, Ng P, Lowenstein PR, Castro MG (2010) A novel bicistronic highcapacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics. J Virol 84:6007-6017.
61. Qiang L, Yang Y, Ma YJ, Chen FH, Zhang LB, Liu W, Qi Q, Lu N, Tao L, Wang XT, You QD, Guo QL (2009) Isolation and characterization of cancer stem like cells in human glioblastoma cell lines. Cancer Lett 279:13-21.
62. Radaelli E, Ceruti R, Patton V, Russo M, Degrassi A, Croci V, Caprera F, Stortini G, Scanziani E, Pesenti E, Alzani R (2009) Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease. Histol Histopathol 24:879-891.
63. Regina A, Demeule M, Berube A, Moumdjian R, Berthelet F, Beliveau R (2003) Differences in multidrug resistance phenotype and matrix metalloproteinases activity between endothelial cells from normal brain and glioma. J Neurochem 84:316-324.
64. Roberts WG, Delaat J, Nagane M, Huang S, Cavenee WK, Palade GE (1998) Host microvasculature influence on tumor vascular morphology and endothelial gene expression. Am J Pathol 153:1239-1248.
65. Roggendorf W, Strupp S, Paulus W (1996) Distribution and characterization of microglia/macrophages in human brain tumors. Acta Neuropathol 92:288-293.
66. Rong Y, Durden DL, Van Meir EG, Brat DJ (2006) 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol 65:529-539.
67. Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, Schmidt K, Kieran MW, Luster AD, Segal RA (2003) A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA 100:13513-13518.
68. San-Galli F, Vrignaud P, Robert J, Coindre JM, Cohadon F (1989) Assessment of the experimental model of transplanted C6 glioblastoma in Wistar rats. J Neurooncol 7:299-304.
69. Sawada T, Kato Y, Sakayori N, Takekawa Y, Kobayashi M (1999) Expression of the multidrug-resistance P-glycoprotein (Pgp, MDR-1) by endothelial cells of the neovasculature in central nervous system tumors. Brain Tumor Pathol 16:23-27.
70. Schlegel J, Piontek G, Kersting M, Schuermann M, Kappler R, Scherthan H, Weghorst C, Buzard G, Mennel H (1999) The p16/Cdkn2a/Ink4a gene is frequently deleted in nitrosourea-induced rat glial tumors. Pathobiology 67:202-206.
71. Schmidek HH, Nielsen SL, Schiller AL, Messer J (1971) Morphological studies of rat brain tumors induced by N-nitrosomethylurea. J Neurosurg 34:335-340.
72. Seligman AM, Shear MJ (1939) Experimental production of brain tumors in mice with methylcholanthrene. Am J Cancer 37:364-395.
73. Shapiro WR, Ausman JI, Rall DP (1970) Studies on the chemotherapy of experimental brain tumors: evaluation of 1,3-bis(2-chloroethyl)-lnitrosourea, cyclophosphamide, mithramycin, and methotrexate. Cancer Res 30:2401-2413.
74. Shelton LM, Mukherjee P, Huysentruyt LC, Urits I, Rosenberg JA, Seyfried TN (2010) A novel pre-clinical in vivo mouse model for malignant brain tumor growth and invasion. J Neurooncol 99:165-176.
75. Sibenaller ZA, Etame AB, Ali MM, Barua M, Braun TA, Casavant TL, Ryken TC (2005) Genetic characterization of commonly used glioma cell lines in the rat animal model system. Neurosurg Focus 19:E1.
76. Sonabend AM, Ulasov IV, Lesniak MS (2007) Emerging role of new transgenic mouse models in glioma research. Expert Rev Anticancer Ther 7:S7-S13.
77. Stojiljkovic M, Piperski V, Dacevic M, Rakic L, Ruzdijic S, Kanazir S (2003) Characterization of 9L glioma model of the Wistar rat. J Neurooncol 63:1-7.
78. Szatmari T, Lumniczky K, Desaknai S, Trajcevski S, Hidvegi EJ, Hamada H, and Safrany G (2006) Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci 97:546-553.
79. Trojan LA, Kopinski P, Mazurek A, Chyczewski L, Ly A, Jarocki P, Niklinski J, Shevelev A, Trzos R, Pan Y, Gitis DJ, Bierwagen M, Czapiewska JL, Wei MX, Michalkiewicz J, Henin D, Popiela T, Evrard F, Kasprzak H, Anthony D, Trojan J (2003) IGF-I triple helix gene therapy of rat and human gliomas. Rocz Akad Med Bialymst 48:18-27.
80. Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN (1996) CDKN2/ p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56:150-153.
81. Valdes PA, Samkoe K, O'Hara JA, Roberts DW, Paulsen KD, Pogue BW (2010) Deferoxamine iron chelation increases delta-aminolevulinic acid induced protoporphyrin IX in xenograft glioma model. Photochem Photobiol 86:471-5.
82. van Asperen J, Mayer U, van Tellingen O, Beijnen JH (1997) The functional role of P-glycoprotein in the blood-brain barrier. J Pharm Sci 86:881-884.
83. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ (2010) Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 60:166-193.
84. Viapiano MS, Hockfield S, Matthews RT (2008) BEHAB/brevican requires ADAMTS-mediated proteolytic cleavage to promote glioma invasion. J Neurooncol 88:261-272.
85. Wen P, Loeffler JS, Morris JH, Lampson LA (1990) The effects of irradiation on major histocompatibility complex expression and lymphocytic infiltration in the normal rat brain and the 9L gliosarcoma brain tumor model. J Neuroimmunol 27:239-244.
86. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492-507.
87. Whittle IR, Macarthur DC, Malcolm GP, Li M, Washington K, Ironside JW (1998) Can experimental models of rodent implantation glioma be improved? A study of pure and mixed glioma cell line tumours. J Neurooncol 36:231-242.
88. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL (2000) Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88:2606-2618.
89. Zagzag D, Lukyanov Y, Lan L, Ali MA, Esencay M, Mendez O, Yee H, Voura EB, Newcomb EW (2006) Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 86:1221-1232.
90. Zagzag D, Esencay M, Mendez O, Yee H, Smirnova I, Huang Y, Chiriboga L, Lukyanov E, Liu M, Newcomb EW (2008) Hypoxia-and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/ CXCR4 expression in glioblastomas: one plausible explanation of Scherer's structures. Am J Pathol 173:545-560.
91. Zagzag D, Miller DC, Chiriboga L, Yee H, Newcomb EW (2003) Green fluorescent protein immunohistochemistry as a novel experimental tool for the detection of glioma cell invasion in vivo. Brain Pathol 13:34-37.
92. Zhu X, Fujita M, Snyder LA, Okada H (2010) Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. J Neurooncol, in the press.